These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27917734)

  • 1. Effective Antibiotic Conservation by Emergency Antimicrobial Stewardship During a Drug Shortage.
    Hsueh K; Reyes M; Krekel T; Casabar E; Ritchie DJ; Jafarzadeh SR; Hays AJ; Lane MA; Durkin MJ
    Infect Control Hosp Epidemiol; 2017 Mar; 38(3):356-359. PubMed ID: 27917734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs.
    Barber KE; Bell AM; Travis King S; Parham JJ; Stover KR
    Braz J Infect Dis; 2016; 20(6):631-634. PubMed ID: 27609214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Piperacillin/Tazobactam Shortage: Central Restriction and Alternative Recommendations as Effective Antibiotic-Stewardship Intervention at a Maximal Care Hospital].
    Kessel J; Dolff B; Wichelhaus T; Keiner N; Hogardt M; Reinheimer C; Wieters I; Harder S; Kempf VAJ; Stephan C;
    Dtsch Med Wochenschr; 2018 Apr; 143(8):e59-e67. PubMed ID: 29237206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of a Piperacillin/Tazobactam Shortage on Antimicrobial Prescribing and Clostridium difficile Risk in 88 US Medical Centers.
    Gross AE; Johannes RS; Gupta V; Tabak YP; Srinivasan A; Bleasdale SC
    Clin Infect Dis; 2017 Aug; 65(4):613-618. PubMed ID: 28444166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections.
    Mendez MN; Gibbs L; Jacobs RA; McCulloch CE; Winston L; Guglielmo BJ
    Pharmacotherapy; 2006 Jan; 26(1):61-7. PubMed ID: 16509027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the use of broad-spectrum antibiotics after cefepime shortage: a time series analysis.
    Plüss-Suard C; Pannatier A; Ruffieux C; Kronenberg A; Mühlemann K; Zanetti G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):989-94. PubMed ID: 22123703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin-Tazobactam Usage at a Tertiary Pediatric Hospital: An Antimicrobial Stewardship Review.
    Janowski AB; Michaels MG; Martin JM; Green MD
    J Pediatric Infect Dis Soc; 2016 Sep; 5(3):342-5. PubMed ID: 26407269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a "handshake" stewardship program versus a formulary restriction policy on High-End antibiotic use, expenditure, antibiotic resistance, and patient outcome.
    Moghnieh R; Awad L; Abdallah D; Jadayel M; Sinno L; Tamim H; Jisr T; El-Hassan S; Lakkis R; Dabbagh R; Bizri AR
    J Chemother; 2020 Nov; 32(7):368-384. PubMed ID: 32364030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
    Brunetti L; Poustchi S; Cunningham D; Toscani M; Nguyen J; Lim J; Ding Y; Nahass RG
    Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of empiric antibiotic de-escalation in an acute care hospital with an established Antimicrobial Stewardship Program.
    Liu P; Ohl C; Johnson J; Williamson J; Beardsley J; Luther V
    BMC Infect Dis; 2016 Dec; 16(1):751. PubMed ID: 27955625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam.
    Edwards SJ; Wordsworth S; Clarke MJ
    Eur J Health Econ; 2012 Apr; 13(2):181-92. PubMed ID: 21243514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
    McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
    Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shifts in antimicrobial consumption and infection rates before and during a piperacillin/tazobactam shortage.
    King ST; Barber KE; Parham JJ; Stover KR
    J Glob Antimicrob Resist; 2017 Dec; 11():111-113. PubMed ID: 28774865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
    Youssif E; Aseeri M; Khoshhal S
    J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
    Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
    JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of antimicrobial stewardship (AS) for appropriate use of antimicrobial agents.
    Matsuoka T; Kato M; Shinoda Y; Ohashi K; Yoshida S; Mori T; Tachi T; Yoshimura T; Teramachi H
    Pharmazie; 2017 May; 72(5):296-299. PubMed ID: 29441876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 19. Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients.
    Sezgin G; Acipayam C; Ozkan A; Bayram I; Tanyeli A
    Asian Pac J Cancer Prev; 2014; 15(11):4549-53. PubMed ID: 24969883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ; Cappelletty DM;
    Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.